Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. reports clinical-stage oncology developments centered on targeted radiopharmaceuticals for solid tumors. The company’s miniprotein radioconjugate platform supports AKY-1189, a Nectin-4 program with potential across urothelial, breast, non-small cell lung, colorectal, cervical, and head and neck cancers, and AKY-2519, a B7-H3 program for prostate, lung, colorectal, and other solid tumors.
Recurring updates include FDA actions such as IND clearances and Fast Track designation, clinical-trial initiations, imaging and dosimetry data presentations, business and financial results, investor-conference participation, and board and committee changes. News also covers Aktis’ collaboration with Eli Lilly and Company to develop radioconjugates outside its proprietary pipeline.
Akoustis Technologies (AKTS) has entered a strategic purchase agreement with a tier-1 enterprise WiFi OEM customer for new WiFi 6E XBAW filters operating above 5 GHz. These filters will function within the recently approved 6 GHz unlicensed spectrum for next-generation WiFi 6E applications. Initial product design has commenced, with sample delivery expected by December 2020. The company aims to capture significant market opportunities in the emerging WiFi 6E sector as demand for high-frequency filters rises.
Akoustis Technologies has announced the launch of its first 5.5 GHz XBAW™ filter module designed for WiFi 6E, covering the 5.1-5.8 GHz spectrum with a notable 665 MHz bandwidth. This product is marketed to reduce interference while enhancing data throughput in high-band WiFi environments. Additionally, multiple samples have been shipped to SoC and OEM partners. The new module is part of Akoustis' strategy to lead in the high-frequency RF filter space, aligning with recent FCC spectrum approvals, which facilitate the expansion of WiFi technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.